Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain

Kurt Banz, Helge Bischoff, Matthias Brunner, Christos Chouaid, Javier de Castro Carpeño, Filippo de Marinis, Francesco Grossi, Alain Vergnenègre, Stefan Walzer

Research output: Contribution to journalArticle

Fingerprint Dive into the research topics of 'Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain'. Together they form a unique fingerprint.

Medicine & Life Sciences